Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corp (NQ: ABUS )

3.050 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 3.050
Bid (Size) 3.040 (23)
Ask (Size) 3.100 (26)
Prev. Close 3.050
Today's Range 3.050 - 3.050
52wk Range 1.690 - 3.640
Shares Outstanding 99,161,234
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
From Arbutus Biopharma Corporation
Via GlobeNewswire

Performance

YTD
+17.76%
+17.76%
1 Month
-7.29%
-7.29%
3 Month
+22.49%
+22.49%
6 Month
+27.62%
+27.62%
1 Year
+34.96%
+34.96%

More News

Read More
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
From Arbutus Biopharma Corporation
Via GlobeNewswire
Earnings Scheduled For February 29, 2024
Via Benzinga
Arbutus to Participate in Jefferies Global Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Present Imdusiran Data at EASL Congress 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
From Whitefort Capital Management, LP
Via Business Wire
Arbutus to Participate in Two Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
Via InvestorPlace
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Arbutus to Participate in Two Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
From Barinthus Biotherapeutics
Via GlobeNewswire
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.